Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company whose news flow is closely tied to the development of its lead drug candidate, GT-02287, and to progress in its broader allosteric small molecule pipeline. The company focuses on next generation allosteric therapies targeting neurodegenerative diseases, rare genetic disorders and oncology, with a primary emphasis on Parkinson’s disease.
News about Gain Therapeutics frequently covers clinical milestones for GT-02287, including updates from its Phase 1 and Phase 1b studies in people with Parkinson’s disease with or without a GBA1 mutation. Press releases have detailed safety and tolerability findings, exploratory biomarker data such as reductions in glucosylsphingosine (GluSph) in cerebrospinal fluid, and observations related to Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) scores. These items provide insight into how the company interprets GT-02287’s potential disease-modifying effects and mechanism of action.
Investors and observers can also expect regular announcements on preclinical research and scientific presentations. Gain Therapeutics reports data from preclinical models that explore GCase modulation, mitochondrial and lysosomal health, and neuroprotection in Parkinson’s disease. Poster presentations at scientific meetings, such as Neuroscience conferences and Parkinson’s-focused congresses, are common subjects of the company’s news releases.
Additional news items include corporate updates and financial disclosures, such as quarterly financial results, capital raises, changes in board composition, and shareholder meeting outcomes. The company also issues notices about participation in investor conferences, key opinion leader (KOL) events, and webinars that discuss biomarkers, clinical endpoints and emerging data from GT-02287 studies.
For readers following GANX, the news page provides a centralized view of clinical trial progress, scientific data, regulatory and corporate developments, and event participation related to Gain Therapeutics’ efforts in allosteric small molecule drug development.
Gain Therapeutics (NASDAQ: GANX) has unveiled promising pre-clinical data on its Gaucher Disease program at the 18th Annual WORLDSymposium. The study demonstrated that its STARs compounds significantly increase GCase protein levels, diminish inflammatory cytokines, and enhance lysosomal functions in GD-iPSC-derived dopaminergic neurons. These findings validate the company’s drug discovery platform, SEE-Tx®, and indicate potential for a first-in-class therapy. Gain aims to commence IND-enabling studies in Q4 2022, addressing unmet needs in neuronopathic Gaucher Disease treatment.
Gain Therapeutics (Nasdaq: GANX) held its inaugural R&D day webinar, highlighting its advancements in drug discovery through the SEE-Tx platform. The company focuses on developing treatments for GBA1 Parkinson's and Gaucher diseases, alongside other lysosomal storage disorders and metabolic diseases. Key 2022 priorities include initiating a Phase 1 trial for GBA1 Parkinson's and advancing its Gaucher disease program. Their innovative approach leverages new computational methods to identify allosteric targets and accelerate drug discovery.
Gain Therapeutics (Nasdaq: GANX) announced its upcoming R&D Day on February 4, 2022, focusing on utilizing computational technology for allosteric drug discovery. The event will feature expert presentations discussing advancements in targeting undruggable proteins, including key topics on neurodegenerative diseases and oncology. Gain's proprietary SEE-Tx® Platform aims to transform drug discovery by identifying novel allosteric targets. The event is expected to shed light on Gain's pipeline and recent research data relevant to treatments for conditions like Parkinson's and Gaucher Disease.
Gain Therapeutics (Nasdaq: GANX), a biotechnology company, has announced an upcoming R&D Day Event and participation in significant scientific conferences addressing neurodegenerative diseases. The R&D Day, titled "Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable", is scheduled for February 4, 2022, at 10:00 a.m. ET. Additionally, Gain will be present at the 18th Annual WORLDSymposium from February 7-11, 2022, and the AD/PD™ 2022 Conference from March 15-20, 2022.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced CEO Eric Richman will participate in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. This virtual event will enable investor access via webcast, available for 90 days post-event. Gain Therapeutics focuses on innovative drug discovery, particularly targeting allosteric binding sites related to neurodegenerative diseases and lysosomal storage disorders. Supported by notable foundations and programs, the company aims to provide new treatment options for challenging disorders linked to protein misfolding.
Gain Therapeutics, Inc. (Nasdaq: GANX) granted Chief Operating Officer Matthias Alder an option to purchase 200,000 shares and 200,000 restricted stock units. These incentives, part of the 2021 Inducement Equity Incentive Plan, aim to motivate Alder upon joining the company. The options will vest over four years, with a $5.86 exercise price per share, matching the closing stock price on December 22, 2021. The restricted units' vesting is contingent on business and clinical milestones. Gain focuses on innovative treatments for neurodegenerative diseases.
Gain Therapeutics (Nasdaq: GANX) provided a scientific update on its Krabbe disease program, highlighting statistically significant increases in the GALC enzyme and a reduction in toxic substrate psychosine. This breakthrough suggests potential treatment options for patients with Krabbe disease, a severe genetic disorder affecting the nervous system. Initial tests on compounds showed promise in reducing psychosine levels. The next phase involves further evaluation of compounds in complex in vitro models.
Gain Therapeutics, Inc. (Nasdaq: GANX) will present a corporate overview at the Imagine AI + Healthcare Investor Summit on December 7, 2021. CEO Eric Richman and Chief Scientific Officer Xavier Barril, Ph.D., will discuss Gain's innovative approach to targeting allosteric binding sites for neurodegenerative diseases and lysosomal storage disorders. The summit is an opportunity for investors to engage with various companies and learn about advancements in AI within healthcare.
Gain Therapeutics (NASDAQ: GANX) reported its Q3 2021 financial results and announced key corporate developments. The company has $40.98 million in cash, providing a strong financial runway into the second half of 2023. Significant progress was made in patient-derived iPSC studies, showing STAR compounds positively affecting Gaucher and Parkinson's disease markers. Matthias Alder was appointed COO, and a five-member Scientific Advisory Board was established to advance the company’s clinical programs. Q3 revenues increased to $27 thousand, while net loss rose to $4.66 million, reflecting higher R&D and administrative expenses.
Gain Therapeutics (Nasdaq: GANX) presented promising preclinical data on GT-02287, a compound targeting glucocerebrosidase (GCase) for Parkinson’s Disease, at the Society for Neuroscience Annual Meeting. The findings revealed that GT-02287 significantly reduced alpha-synuclein pathology and neuroinflammation while improving behavioral deficits in an animal model. With a favorable toxicity profile, this orally bioavailable compound shows potential in addressing unmet needs for patients suffering from Parkinson’s, particularly those with GBA1 mutations.